Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive without efficacy , is a new generation of highly efficient antihypertensive .
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Valsartan is an angiotensin II receptor antagonistwith particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure. In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI) .
Muna da masana'antu masu inganci da yawa tare da haɗin gwiwa mai zurfi, wanda zai iya ba ku samfuran inganci da farashin gasa. Kuma muna iya ba da rangwamen kuɗi don sayayya mai yawa. Kuma muna ba da haɗin kai tare da ƙwararrun kamfanoni masu jigilar kaya, za su iya isar da samfuran cikin aminci da kwanciyar hankali ga hannunku. Lokacin bayarwa shine kimanin kwanaki 3-20 bayan tabbatar da biyan kuɗi.
Abu | Test Standard | Testing Result | |
Bayyanar | Powder | Ya bi | |
Color | Farin foda | Ya bi | |
Particle Size | 100% pass 80 mesh | Ya bi | |
Oder | Characteristic | Ya bi | |
Taste | Characteristic | Ya bi | |
Asara akan bushewa | ≤5.0% | 2.20% | |
Residue on Ignition | ≤0.1% | 0.05% | |
Residual acetone | ≤0.1% | Ya bi | |
Residual Ethanol | ≤0.5% | Ya bi | |
Heave Mentals | ≤10ppm | Ya bi | |
Na | ≤0.1% | <0.1% | |
Pb | ≤3 ppm | Ya bi | |
Jimlar Faranti | <1000CFU/g | Ya bi | |
Yeast & Mold | <100 CFU /g | Ya bi | |
E. Coli | Korau | Ya bi | |
Salmonella | Korau | Ya bi | |
Conclusion: Conform with USP Standard |
1. Shin ku masana'anta ne ko kamfani na kasuwanci?
Mu kamfani ne mai haɗa masana'antu da kasuwanci, samar da sabis na tsayawa ɗaya. Ana iya karɓar OEM.
2. Kuna samar da samfurori? Yana da kyauta ko kari?
Samfuran kyauta. Ana buƙatar biyan kuɗin jigilar samfurin ta gefen ku.
3. Kuna da wasu takaddun shaida masu alaƙa da kula da inganci?
ISO 9001: 2008 takardar shaida don tabbatar da inganci.
4. Menene zan bayar don samun zance?
Pls sanar da mu nau'in samfurin wanda kuke buƙata, adadin oda, adireshi da takamaiman buƙatu. Za a yi zance don bayanin ku cikin lokaci.
5. Wane irin hanyar biyan kuɗi kuka fi so? Wane irin sharuɗɗan ne ake karɓa?
Sharuɗɗan Isar da Karɓa: FOB, CFR, CIF, EXW;
Kudin Biyan Da Aka Karɓa: USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Harshe Ana Magana: Turanci.
Rukunin samfuran